Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review

Ippazio Cosimo Antonazzo, Giorgia Gribaudo (), Adriano Vecchia, Pietro Ferrara, Alexandra Piraino, Paolo Angelo Cortesi and Lorenzo Giovanni Mantovani
Additional contact information
Ippazio Cosimo Antonazzo: University of Milan-Bicocca
Giorgia Gribaudo: University of Milan-Bicocca
Adriano Vecchia: University of Milan-Bicocca
Pietro Ferrara: University of Milan-Bicocca
Alexandra Piraino: University of Milan-Bicocca
Paolo Angelo Cortesi: University of Milan-Bicocca
Lorenzo Giovanni Mantovani: University of Milan-Bicocca

PharmacoEconomics, 2024, vol. 42, issue 12, No 3, 1329-1343

Abstract: Abstract Background Psoriatic arthritis (PsA) is an inflammatory disease characterised by a variety of clinical manifestations. Considering the economic burden posed by PsA and the increasing number of treatment options, economic evaluations are required to better allocate available resources. This work aims to update a previous published literature review on PsA cost-of-illness and cost-effectiveness analysis. Methods A search was performed of English-language literature between January 2017 and March 20, 2024 in Medline/PubMed, Embase and Cochrane library using the terms ‘psoriatic arthritis’, ‘cost of illness’ and ‘cost effectiveness’. Data on decision model, time horizon, population, treatment options, perspective, type of costs, relevant results and authors’ conclusion were extracted from the reviewed articles. Finally, the quality of the included studies was evaluated. Results Twenty-seven studies met the inclusion criteria: 16 cost-of-illness and 11 cost-effectiveness/cost-utility analyses. PsA is characterised by high direct and indirect costs. Drug costs as well as hospitalisation and absenteeism were the major drivers of the observed costs. The cost-effectiveness analyses reported the dominance or the cost effectiveness of biologic therapies compared with non-biologic PsA treatment. Biological options like bimekizumab and ixekizumab have demonstrated a better cost-effectiveness profile in PsA patients compared with other treatments (i.e., other biological treatments). Conclusions There was an increased number of economic evaluations compared with the previous review. PsA is still associated with significant economic burden worldwide. The main cost was represented by therapies, specifically biological therapies. Amongst the biological therapies, bimekizumab and ixekizumab appear to provide the most economic benefit. Finally, new economic studies are needed to enrich knowledge on the economic burden of subgroups of PsA patients as well as early treatment of PsA with new therapies.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-024-01428-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:12:d:10.1007_s40273-024-01428-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-024-01428-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().